Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Conditions
- NSCLC
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Eikon Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT06246110
- Locations
- 🇺🇸
Bioresearch Partner, Hialeah, Florida, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Providence St Joseph Hospital, Center for Cancer Prevention and Treatment, Orange, California, United States
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
Renovatio Clinical /ID# 261999, The Woodlands, Texas, United States
🇺🇸Moores Cancer Center /ID# 267782, La Jolla, California, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- Conditions
- Metastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan
Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC
- Conditions
- Non-Small Cell Lung Cancer, NSCLCKRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung CancerLung Cancer Stage IV, Advanced Solid Tumor, CancerRAS G12D-mutated NSCLC
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT06162221
- Locations
- 🇮🇹
Ospedale Santa Maria Delle Croci, Ravenna, Italy
🇮🇹IRCCS Instituto Nazionale tumori Ragina Elena, Rome, Italy
🇮🇹Fondazione Policlinico Universitario A Gemelli-Rome, Rome, Italy
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Resectable Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇷🇴
Medisprof Cancer Center, Cluj-Napoca, Cluj, Romania
🇲🇾Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia
🇲🇾Hospital Umum Sarawak, Kuching, Malaysia
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
- Conditions
- Pleural Mesothelioma
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 40
- Registration Number
- NCT06155279
- Locations
- 🇮🇹
Humanitas Gavazzeni, Bergamo, Italia/Bergamo, Italy
🇮🇹Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Conditions
- Lung Cancer, Non-squamous, Non-small Cell
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT06151574
- Locations
- 🇫🇷
HOP Civil, Strasbourg, France
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Mohtaseb Cancer Center and Blood Disorders, LLC, Bullhead City, Arizona, United States
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell LungNeoplasm Metastasis
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1016
- Registration Number
- NCT06119581
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Banner University Medical Center Phoenix, Phoenix, Arizona, United States
A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: TQB2450 injectionDrug: AL2846 capsule
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06116240
- Locations
- 🇨🇳
Jiangmen Central Hospital, Jiangmen, Guangdong, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Target Recruit Count
- 314
- Registration Number
- NCT06110663
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.